HC Wainwright Reiterates Buy Rating for Tetraphase Pharmaceuticals (TTPH)

Share on StockTwits

Tetraphase Pharmaceuticals (NASDAQ:TTPH)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report issued on Monday.

Several other equities research analysts have also recently weighed in on TTPH. Gabelli raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 29th. ValuEngine raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Finally, Zacks Investment Research cut shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 7th. One analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $7.22.

Shares of TTPH opened at $3.09 on Monday. The firm has a market cap of $160.46 million, a price-to-earnings ratio of -1.17 and a beta of 2.60. Tetraphase Pharmaceuticals has a twelve month low of $2.05 and a twelve month high of $8.75.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.04. The business had revenue of $1.89 million during the quarter, compared to analysts’ expectations of $1.88 million. Tetraphase Pharmaceuticals had a negative net margin of 1,061.06% and a negative return on equity of 85.70%. equities research analysts expect that Tetraphase Pharmaceuticals will post -1.56 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. Paloma Partners Management Co purchased a new stake in shares of Tetraphase Pharmaceuticals in the 4th quarter worth about $210,000. Dynamic Technology Lab Private Ltd lifted its position in shares of Tetraphase Pharmaceuticals by 322.1% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,108 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 58,079 shares during the period. Alambic Investment Management L.P. purchased a new stake in shares of Tetraphase Pharmaceuticals in the 1st quarter worth about $356,000. Two Sigma Investments LP lifted its position in shares of Tetraphase Pharmaceuticals by 276.7% in the 4th quarter. Two Sigma Investments LP now owns 64,413 shares of the biopharmaceutical company’s stock worth $406,000 after purchasing an additional 47,313 shares during the period. Finally, A.R.T. Advisors LLC purchased a new stake in shares of Tetraphase Pharmaceuticals in the 1st quarter worth about $807,000. 44.60% of the stock is owned by hedge funds and other institutional investors.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Article: What kind of dividend yield to CEF’s pay?

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Symantec  Price Target Increased to $20.00 by Analysts at Deutsche Bank
Symantec Price Target Increased to $20.00 by Analysts at Deutsche Bank
Barrington Research Lowers Lions Gate Entertainment Corp. Class A  Price Target to $27.00
Barrington Research Lowers Lions Gate Entertainment Corp. Class A Price Target to $27.00
News Corp Class A  Upgraded to “Hold” at Zacks Investment Research
News Corp Class A Upgraded to “Hold” at Zacks Investment Research
Covia  Receives “Buy” Rating from Jefferies Financial Group
Covia Receives “Buy” Rating from Jefferies Financial Group
$0.50 EPS Expected for Government Properties Income Trust  This Quarter
$0.50 EPS Expected for Government Properties Income Trust This Quarter
Paragon  Price Hits $0.0702 on Top Exchanges
Paragon Price Hits $0.0702 on Top Exchanges


© 2006-2018 Ticker Report. Google+.